Finding – Page 6

CDC advisors broaden RSV vaccine recommendations to at-risk adults in their 50s

3 months ago talkbio0Tagged 50–59, Adult, Age, Arexvy, broaden, Centers for Disease Control and Prevention (U.S.), Chronic Condition, Recommendation, Respiratory syncytial virus, Severe (severity modifier), Vaccines

Adult, Respiratory syncytial virus, Centers for Disease Control and Prevention (U.S.), Vaccines, Recommendation, Age, Arexvy, Chronic Condition, Severe (severity modifier), 50–59, broaden

Glycomine raises $115M to see if it can treat rare glycosylation disorder

3 months ago talkbio0Tagged Congenital disorder of glycosylation type 1A, GLM101, Glycomine, Infrequent

Infrequent, GLM101, Glycomine, Congenital disorder of glycosylation type 1A

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

3 months ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Trump pledges his support for a change to the IRA long sought by drugmakers

3 months ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

Sanofi tempers its OX40 expectations in asthma after mid-stage miss

3 months ago talkbio0Tagged Amlitelimab, Asthma, exacerbations, Expectations, sanofi, Subgroup A Nepoviruses, TNFRSF4 gene

Asthma, Amlitelimab, TNFRSF4 gene, sanofi, exacerbations, Subgroup A Nepoviruses, Expectations

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

3 months ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Vaccine-probiotic combo prevents, clears bacterial gut infections in mice in antibiotic alternative test

3 months ago talkbio0Tagged Antibiotics, House mice, Immune response, Probiotics, Vaccines

Antibiotics, Probiotics, House mice, Immune response, Vaccines

Dexcom extends G7 sensor wear time to 15 days with latest FDA nod

4 months ago talkbio0Tagged Accurate (qualifier), Continuous glucose monitoring, day, Extension, MSH5 gene, sensor (device), United States Food and Drug Administration, wear time

United States Food and Drug Administration, sensor (device), Continuous glucose monitoring, MSH5 gene, Accurate (qualifier), Extension, wear time, day